Apellis Pharmaceuticals Inc APLS.OQ APLS.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025
The Waltham Massachusetts-based company is expected to report a 14.0% increase in revenue to $196.485 million from $172.33 million a year ago, according to the mean estimate from 21 analysts, based on LSEG data.
LSEG's mean analyst estimate for Apellis Pharmaceuticals Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.
Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $41.50, above its last closing price of $20.34.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.39 | -0.39 | -0.29 | Beat | 24.8 |
Sep. 30 2024 | -0.30 | -0.30 | -0.46 | Missed | -53.3 |
Jun. 30 2024 | -0.30 | -0.32 | -0.28 | Beat | 13.5 |
Mar. 31 2024 | -0.50 | -0.47 | -0.42 | Beat | 10 |
Dec. 31 2023 | -0.67 | -0.69 | -0.73 | Missed | -6.4 |
Sep. 30 2023 | -0.80 | -0.86 | -1.17 | Missed | -36.8 |
Jun. 30 2023 | -1.32 | -1.32 | -1.02 | Beat | 22.9 |
Mar. 31 2023 | -1.50 | -1.46 | -1.56 | Missed | -6.5 |
This summary was machine generated May 5 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。